Pharma Combats Regulators With Smaller 'Tuck-In' Deals

The video discusses Allergan's shift to smaller M&A deals after a failed merger with Pfizer. It explores trends in the healthcare sector, noting a move away from mega deals due to regulatory challenges and economic conditions. The discussion highlights the impact of regulatory pushback, such as antitrust issues and new inversion rules, on large deals. It also examines market conditions, including the effects of Brexit and interest rates, on M&A activity and investment opportunities.

What is Allergan's current approach to mergers and acquisitions according to Brent Saunders?

What factors are influencing the trend away from large mega deals in the healthcare industry?

What concerns did the speaker express about the future of M&A activity in the coming months?

What is the significance of the presidential election mentioned in relation to M&A activity?

How has the regulatory environment affected M&A activity in the pharmaceutical sector?